Camurus Receives Approval to Start Phase II Trial of CAM2028

Camurus AB has received approval to begin a Phase II proof-of-concept clinical trial of CAM2028 for the treatment of pain in oral mucositis. The multicenter trial will be conducted in the EU and enrolment of the first patient begins in March 2007.

CAM2028 is a mucoadhesive, extended-release formulation of benzydamine, a local anaesthetic with anti-inflammatory and antibacterial properties, designed for the treatment of oral mucositis in cancer patients. CAM2028 aims to provide an extended analgesic effect as well as protection for damaged mucosal surfaces. The product is based on the proprietary FluidCrystal drug delivery system and is administered as a lipid-based solution that spreads across damaged mucosal surfaces. Directly after administration, CAM2028 forms a mucoprotective and drug encapsulating liquid crystal gel, providing extended release of benzydamine.

For further information please contact:

Fredrik Tiberg,

CEO

Tel: +46 046 286 3863,

Mail: info@camurus.com

Or visit www.camurus.com